GlassScriptPhysician profile
Kiran H Clair
NPI 1629481908
$2,248.64
in general payments reported to CMS, 2019-2025
15 companies · $344 in 2025
The $344 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $124 · 2021: $685 · 2022: $188 · 2023: $43.52 · 2024: $501 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $888.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $843.01 | 2019-2024 | Lynparza |
| Merck Sharp & Dohme LLC | $326.32 | 2023-2025 | Keytruda, Lynparza |
| Glaxosmithkline, LLC. | $252.79 | 2021-2025 | Jemperli |
| Myriad Genetic Laboratories, INC. | $244.48 | 2021-2024 | Myrisk |
| Clovis Oncology, INC. | $123.44 | 2019 | |
| Eisai INC. | $113.63 | 2019-2022 | |
| Seagen INC. | $92.06 | 2022 | |
| Novartis Pharmaceuticals Corporation | $65.96 | 2025 | |
| Daiichi Sankyo INC. | $49.02 | 2024-2025 | Enhertu |
| Puma Biotechnology, INC. | $28.77 | 2024 | |
| Immunogen, INC. | $27.88 | 2023 | Elahere |
| Abbvie INC. | $27.26 | 2025 | |
| Gilead Sciences, INC. | $23.31 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $17.10 | 2024 | Sancuso |
| Ethicon US, LLC | $13.61 | 2025 | Echelon Circular |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kiran Clair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.